147 related articles for article (PubMed ID: 38520513)
1. Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics.
García-Zoghby L; Amo-Salas M; Soriano Castrejón ÁM; García Vicente AM
Eur J Nucl Med Mol Imaging; 2024 Mar; ():. PubMed ID: 38520513
[TBL] [Abstract][Full Text] [Related]
2. Head-to-Head Comparison of [
García-Zoghby L; Lucas-Lucas C; Amo-Salas M; Soriano-Castrejón ÁM; García-Vicente AM
Curr Oncol; 2023 Jun; 30(7):6271-6288. PubMed ID: 37504324
[TBL] [Abstract][Full Text] [Related]
3. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
4. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6.
Mena E; Lindenberg ML; Turkbey IB; Shih JH; Harmon SA; Lim I; Lin F; Adler S; Eclarinal P; McKinney YL; Citrin D; Dahut W; Wood BJ; Krishnasamy V; Chang R; Levy E; Merino M; Pinto P; Eary JF; Choyke PL
J Nucl Med; 2020 Jun; 61(6):881-889. PubMed ID: 31676732
[TBL] [Abstract][Full Text] [Related]
7. Predictors of
Mena E; Rowe SP; Shih JH; Lindenberg L; Turkbey B; Fourquet A; Lin FI; Adler S; Eclarinal P; McKinney YL; Citrin DE; Dahut W; Wood BJ; Chang R; Levy E; Merino M; Gorin MA; Pomper MG; Pinto PA; Eary JF; Choyke PL; Pienta KJ
J Nucl Med; 2022 Aug; 63(8):1184-1190. PubMed ID: 34916246
[TBL] [Abstract][Full Text] [Related]
8. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
[TBL] [Abstract][Full Text] [Related]
9. Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study.
García Vicente AM; Lucas Lucas C; Pérez-Beteta J; Borrelli P; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM
Sci Rep; 2024 Feb; 14(1):3001. PubMed ID: 38321201
[TBL] [Abstract][Full Text] [Related]
10. Pathological predictors of
Perry E; Talwar A; Taubman K; Ng M; Wong LM; Sutherland TR
BJU Int; 2022 Jun; 130 Suppl 1(Suppl 1):28-36. PubMed ID: 35768883
[TBL] [Abstract][Full Text] [Related]
11. Patterns of disease detection using [
Koschel S; Taubman K; Sutherland T; Yap K; Chao M; Guerrieri M; Benson A; Starmans M; Byrne G; Ong G; Macleod C; Foo M; Wong LM; Gyomber D; Ng M
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3712-3722. PubMed ID: 33852051
[TBL] [Abstract][Full Text] [Related]
12. Risk of metastatic disease using [
Chikatamarla VA; Okano S; Jenvey P; Ansaldo A; Roberts MJ; Ramsay SC; Thomas PA; Pattison DA
EJNMMI Res; 2021 Dec; 11(1):128. PubMed ID: 34928437
[TBL] [Abstract][Full Text] [Related]
13. Changes in Management After
Ng M; Guerrieri M; Wong LM; Taubman K; Sutherland T; Benson A; Byrne G; Koschel S; Yap K; Starmans M; Ong G; Macleod C; Foo M; Chao M
J Nucl Med; 2022 Sep; 63(9):1343-1348. PubMed ID: 35058320
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and therapeutic impact of PET/CT with 18F-DCFPyL versus 18F-Fluorocholine in initial staging of intermediate-/high-risk prostate cancer: a pilot study.
Lucas Lucas C; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM; García Vicente AM
Ann Nucl Med; 2023 Oct; 37(10):551-560. PubMed ID: 37532975
[TBL] [Abstract][Full Text] [Related]
16. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
Marzola MC; Chondrogiannis S; Ferretti A; Grassetto G; Rampin L; Massaro A; Castellucci P; Picchio M; Al-Nahhas A; Colletti PM; Marcolongo A; Rubello D
Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
[TBL] [Abstract][Full Text] [Related]
17. PSA-Stratified Performance of [
Harsini S; Wilson D; Bénard F
Diagnostics (Basel); 2022 Sep; 12(9):. PubMed ID: 36140613
[TBL] [Abstract][Full Text] [Related]
18. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract][Full Text] [Related]
19. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
Ceci F; Castellucci P; Mamede M; Schiavina R; Rubello D; Fuccio C; Ambrosini V; Boschi S; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate Cancer Patients After Definitive Treatment With PSA Level ≤0.2 ng/mL.
Lu Y; Wilson ZJ; Xu G; Xu Z; Pan T; Wei P
Clin Nucl Med; 2023 Dec; 48(12):1021-1027. PubMed ID: 37801580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
